saroglitazar magnesium

Saroglitazar magnesium is a dual peroxisome proliferator-activated receptor (PPAR) agonist. It is the magnesium salt (2:1) of saroglitazar, which is its parent compound. Through dual activation of PPAR-α and PPAR-γ, it aims to regulate both lipid and glucose homeostasis. The PPAR-α activation leads to increased hepatic oxidation of fatty acids, reduced synthesis and secretion of triglycerides, increased lipolysis, activation of lipoprotein lipase (LPL), reduced production of Apo C-III, reduced plasma LDL-C, and increased synthesis of apolipoproteins A-I and A-II, and HDL-C. In India, saroglitazar (as Lipaglyn™) is approved for diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. It is also being investigated for other conditions including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

Brand names

Lipaglyn

Other names

Saroglitazar